To investigate the role of PRMT3 in regulating T cell-mediated anti-tumor immunity, we employed both genetic and pharmacological approaches to determine the effect of Prmt3-KO and PRMT3 inhibition on tumor progression using the Hepa1-6 syngeneic model. This evidence concerns the gene PRMT3 and neoplasm.